Compare FT & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FT | CNTX |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.8M | 209.5M |
| IPO Year | N/A | 2021 |
| Metric | FT | CNTX |
|---|---|---|
| Price | $8.17 | $3.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 66.2K | ★ 997.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | ★ 69.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.71 | $0.49 |
| 52 Week High | $8.35 | $2.86 |
| Indicator | FT | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 76.21 |
| Support Level | $7.79 | $0.95 |
| Resistance Level | $8.20 | N/A |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 32.61 | 85.25 |
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.